3TAMAI I,NAKANISHI T,NAKAHARA H,et al.Improvement of L-Dopa absorption by dipeptidyl derivation,utilizing peptide transporter Pept1[J].J Pharm Sci,1998,87(12):1542-1546. 被引量：1
4HU M,SUBRAMANIAN P,MOSBERG H I,et al.Use of the peptide carrier system to improve the intestinal absorption of L-α-methyldopa:carrier kinetics,intestinal permeabilities,and in vitro hydrolysis of dipeptidyl derivatives of L-α-methyldopa[J].Pharm Res,1989,6(1):66-70. 被引量：1
5HAN H.5'-Amino acid esters of antiviral nucleosides,Acyclovir,and AZT are absorbed by the intestinal PEPTl peptide transporter[J].Pharm Res,1998,15(8):1154-1159. 被引量：1
6CVETKOVIC M,LEAKE B,FROMM M F,et al.OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine[J].Drug Metab Dispos,1999,27(8):866～871. 被引量：1
7HISANG B,ZHU Y,WANG Z,et al.A novel human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitors transporters[J].J Biol Chem,1999,274:37161-37168. 被引量：1
8DRESCHER S,GLAESER H,MURDTER T,et al.P-glycoprotein-mediated intestinal and biliary digoxin transport in humans[J].Clin Pharmacol Ther,2003,73(3):223-231. 被引量：1
9SUN J,HE Z,CHENG G,et al.Multidrug resistance P-glycoprotein:the crucial significances in drug disposition and interaction[J].Med Sci Monitor,2004,10(1):5-14. 被引量：1
10GOTOH Y,SUZUKI H,KINOSHITA S,et al.Involvement of an organic anion transporter (canalicular multispecific organic anion transporter/mulfidrug resistance-associated protein 2) in gastrointestinal secretion of glutathione conjugates in rats[J].J Pharmacol Exp Ther,2000 292(1):433-439. 被引量：1
二级参考文献60
1Jonker JW, Wagenaar E, Moi CA, et al. Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 ( Octl [ Slc22a1) gene[J]. Mol Cell Biol, 2001,21(16) : 5471 - 5477. 被引量：1
2Wang DS, Jonker JW, Kato Y, et al. Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin [ J ]. J Pharmacol Exp Ther,2002,302(2) :510 - 515. 被引量：1
3Tamai l, Yabuuchi H, Nezu Y, et al. Cloning and characterization of a novel human pH-dependent organic cation transporter, OCTN1[J]. FEBS Lett, 1997,419(1) :107 -111. 被引量：1
4Flens MJ, Zaman GJ, Van der Valk P, et al. Tissue distribution of the muhidrug resistance protein[J]. Am J Pathol, 1996,148(4) : 1237 - 1247. 被引量：1
5Ogawa K, Suzuki H, Hirohashi T, et al. Characterization of inducible nature of Mrp3 in rat liver[J]. Am J Physiol, 2000,295 ( 3 ) : G438 - G446. 被引量：1
6Konig J, Rost D, Cui Y, et al. Characterization of the human muhidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane[ J ].Hepatology, 1999,29(4) :1156 - 1163. 被引量：1
7Hirohashi T, Suzuki H, Takikawa H, et al. ATP-dependent transport of bile salts by rat muhidrug resistance-associated protein ( Mrp3 ) [ J ]. J Biol Chem,2000,275 (4) : 2905 - 2910. 被引量：1
9Funk C, Ponelle C, Scheuermann G, et al. Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity, in vivo and in vitro interaction at the canalicular bile salt export pump(Bsep) in the rat [J]. Mol Pharmacol, 2001,59(3):627 - 635. 被引量：1
10Yamazaki M, Akiyama S, Nitnuma K, et al. Biliary excretion of pravastafin in rats: contribution of the excretion pathway mediated by canalicular mulfispecific organic anion transporter[J]. Drug Metab Dispos, 1997,25(10) :1123 - 1129. 被引量：1
2Endres C J, Hsiao P, Chung F S, et al. The role of transport ers in drug interactions[J]. Eur J Pharm Sci, 2006, 27 (5): 501-517. 被引量：1
3Szakacs G, Varadi A, Ozvegy-Laezka C, et al. The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox)[J]. Drug Discov Today, 2008, 13(9 10): 379-393. 被引量：1
4Lin JH. Drug-drug interaction mediated by inhibition and in duction of P glycoprotein[J]. Adv Drug Deliv Rev, 2003, 55 (1): 53-81. 被引量：1
5Vallakati A, Chandra PA, Pednekar M, et al. Droncdarone Induced Digoxin Toxicity: New Drug, New Interactions[J]. Am J Ther, 2011. 被引量：1
6Friedrich C, Ring A, Brand T, et al. Evaluation of the pharmacokinetic interaction after multiple oral doses of linagliptin and digoxin in healthy volunteers[J]. Eur J Drug Metab Phar macokinet, 2011, 36(1) : 17-24. 被引量：1
7Shoal SE, Ohzone Y, Ninomiya S, et al. In vitro P-glycopro tein interactions and steady-state pharmacokinetie interactions between tolvaptan and digoxin in healthy subjects[J]. J Clin Pharmaeol, 2011, 51 (5) : 761-769. 被引量：1
8Aylin Arici M, Kilinc E, Demir O, et al. Interactions between Verapamil and Digoxin in Langendorff Perfused Rat Hearts:The Role of Inhibition of P-glycoprotein in the Heart[J]. Basic Clin Pharmaeol Toxieol,2010, 107(5): 847-852. 被引量：1
9Schmitt C, Kaeser B, Riek M, et al. Effect of saquinavir/ ritonavir on P-glycoprotein activity in healthy volunteers using digoxin as a probe[J]. Int J Clin Pharmacol Ther, 2010, 48 (3): 192-199. 被引量：1
10Oga E F, Sekine S, Shitara Y, et al. Potential P glycoprotein mediated drug-drug interactions of antimalarial agents in Caco-2 cells[J]. Am J Trop Med Hyg, 2012, 87(1): 64-69. 被引量：1
